Wipfli Financial Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Wipfli Financial Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$23K	Buy	+204	New	+$20.6K	﹤0.01%	1519

Other funds holding SRPT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wipfli Financial Advisors's SRPT Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Sarepta Therapeutics (SRPT) in Q3 2022: 204 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #1519 among its holdings.

375 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

Wipfli Financial Advisors held 204 shares of Sarepta Therapeutics worth $23K as of Q3 2022.
Sarepta Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
Sarepta Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1519 holding.
375 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.